Delian Asparouhov

Who they are

Delian Asparouhov is a Partner at Founders Fund — MIT dropout, Thiel Fellow, and co-founder of Varda Space Industries, the orbital pharmaceutical manufacturing company that hit unicorn status in 2025.

Person

Delian attended MIT from 2011 to 2013, dropped out as a Thiel Fellow, and immediately started Nightingale App — a YC Summer 2014 company he ran as CEO through 2016. From there he moved into operations at Teespring as Head of Growth, then pivoted toward venture by becoming Chief of Staff to Keith Rabois at Khosla Ventures. He joined Founders Fund in 2019 as Principal and has since been promoted to Partner at the firm Peter Thiel founded. Running a VC seat and a frontier-tech startup simultaneously, he co-founded Varda Space Industries in 2021 — an orbital manufacturing company that manufactures pharmaceuticals in low Earth orbit and returns them to Earth, reaching a $187 million raise and unicorn status in 2025. He also created the Hill and Valley Forum, a tech-policy gathering, and runs the Operators podcast on Substack (delian.substack.com), which spotlights non-founder, non-VC operators working inside startups — a notably unglamorous subject for someone in his seat. The through-line is a repeated bet on infrastructure that most people think is too early: consumer printing (Teespring), frontier VC (Founders Fund), orbital manufacturing (Varda).

Company

Founders Fund closed Founders Fund Growth IV at $6 billion — its largest growth-stage vehicle — pushing total assets under management past $20 billion. That followed the April 2025 close of Founders Fund Growth III at $4.6 billion, a fund focused on AI and defense. Recent portfolio activity has been substantial: Anduril raised $4 billion at a $60 billion valuation in June 2025, and Cognition — builder of the AI coding agent 'Devin' — raised $1 billion at a $26 billion valuation in June 2026. Founders Fund also committed $1.25 billion into Anthropic's $30 billion round at a $350 billion valuation in 2025, and led Nominal's $80 million Series B-2 in June 2026, pushing that industrial software platform to a $1 billion valuation.

Market

Founders Fund operates in a venture market increasingly dominated by concentrated, growth-stage bets on AI and defense — a posture the firm has held longer than most. Its thesis on frontier technology puts it alongside other multi-billion-dollar growth vehicles competing for access to the same breakout companies. Its portfolio includes Palantir Technologies, SpaceX, and Flock Safety, anchoring it firmly in the defense and aerospace segment where check sizes and geopolitical stakes are rising together.

Network

Delian's most visible professional relationships run through Founders Fund and Varda. He co-founded Varda with Will Bruey in 2021, and joined Founders Fund under Peter Thiel. His earlier career was shaped by Keith Rabois, for whom he served as Chief of Staff at Khosla Ventures.

Will Bruey· Co-founder, Varda Space Industries
Peter Thiel· Founder, Founders Fund
Keith Rabois· Partner, Khosla Ventures (former principal's Chief of Staff relationship)

How they likely show up

Hybrid role pattern — active VC Partner and active company co-founder simultaneously → operates best when he has skin in the game on both sides of the table; unlikely to be satisfied by purely advisory or observer positions.
Built the Operators podcast to spotlight unglamorous, non-founder operators → suggests he values execution depth over narrative glamour and probably asks 'who actually built this?' before he asks 'what's the vision?'
MIT dropout → Thiel Fellow → YC company → Chief of Staff → VC → space founder: each move compresses a conventional timeline → he moves fast and trusts conviction over consensus.
Runs his Substack and podcast alongside a full-time Partner role at a $20B+ AUM fund → high agency, comfortable carrying multiple high-stakes commitments; doesn't wait for permission to start a project.
Content themes cluster tightly around space manufacturing, regulatory challenges in aerospace, and startup ecosystems → his public voice is domain-specific, not generic thought leadership; he's done the technical work.
Chief of Staff background under Keith Rabois → accustomed to operating close to principal decision-makers; likely brings strong pattern-recognition about organizational leverage and where time actually goes.

Conversation tips

→ Reference Varda specifically — the orbital pharmaceutical manufacturing angle, not just 'space startup' — he's clearly invested in the technical specificity of what makes zero-G manufacturing different.
→ Ask about the Operators podcast by name; he chose to platform non-founders and non-VCs, which is a deliberate editorial choice worth probing.
→ He's been in the room at Founders Fund through a historic deployment cycle (Anduril, Anthropic, Cognition) — ask about pattern recognition across those bets rather than any single company.
→ He's Bulgarian-born and has spoken publicly about the journey from Bulgaria to Silicon Valley — if relevant to your context, that origin story is something he's chosen to share.
→ Don't ask him to pick between 'investor' and 'operator' — he clearly runs both tracks deliberately; treat him as both.

Toolbox

Openers

Open on Varda hitting unicorn status after the $187 million raise — he co-founded it while already a Partner at Founders Fund, which is an unusual move that signals something about how he thinks about risk and conviction.
Mention the Operators podcast on his Substack — he built a show specifically for non-founder operators, which is a pointed editorial choice for someone whose own CV is almost entirely founder and investor; ask what gap he was trying to fill.
Reference the SpaceNews piece on orbital data centers — he's publicly argued for that use case, and it's a more provocative extension of the Varda thesis that opens a real conversation about where orbital infrastructure goes next.

Discovery questions

Varda is manufacturing pharmaceuticals in orbit and returning them to Earth — what does the regulatory path actually look like for getting those compounds approved, and how much of the company's timeline is science versus FDA?
You've backed Anduril, Cognition, and Anthropic from Founders Fund while co-founding Varda on the side — how do you decide which frontier bets you take as an investor versus which ones you have to go build yourself?
The Operators podcast deliberately focuses on people who aren't founders or VCs — what did you learn from those conversations that you didn't already know from being inside Founders Fund?

Avoid

Don't treat Varda as a side project or a passion play — it's a unicorn he co-founded and actively chairs, and framing it as secondary to his VC work will read as not having done the homework.

Make it yours